Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SGT-003 gene therapy in ambulatory boys with Duchenne muscular dystrophy
NL-OMON61180Phase 3Not yet recruiting
- Sponsor
- Solid Biosciences
- Start
- Feb 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of SGT-003 in Duchenne muscular dystrophy (DMD), sponsored by Solid Biosciences. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
SGT-003
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON61180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61180.